The LA Times asks:
Question: What does Bristol-Myers Squibb Co. make besides drugs?
Answer: Bad investment decisions.
Bristol-Myers Squibb has revealed a $275m charge to write down illiquid securities with exposure to subprime mortgages.
The move by the US drugmaker came after it marked down by almost half, to $419m, the value of so-called "auction rate securities" previously valued at $811m.
The securities represented interests in structured debt investments backed by collateral that included mortgages - some of which were residential subprime - credit cards, insurance securitisations and corporate bonds.
More at the FT
No comments:
Post a Comment